On May 14, 2026, the CDC added Mauritius to its active travel health notice list with a new chikungunya outbreak alert — making Mauritius the fourth country or territory on the CDC's current active chikungunya warning roster, joining Suriname (since February 2026), Mayotte (since March 10, 2026), and French Guiana (since June 4, 2026). The scale of simultaneous chikungunya outbreaks across two continents and two ocean basins represents the widest geographic spread of concurrent CDC chikungunya travel notices since the catastrophic Indian Ocean outbreaks of 2005 and 2006, which infected an estimated 1.4 million people across Réunion, Mauritius, Mayotte, and the Comoros islands in a single epidemic wave.
Mauritius is a volcanic island nation located in the southwest Indian Ocean, approximately 2,000 kilometers off the southeastern coast of Africa, situated between Madagascar and the Australian subcontinent. It is one of Africa and the Indian Ocean's most sought-after tourist destinations — known for its beaches, resorts, water sports, and biodiversity — and receives hundreds of thousands of international visitors annually, including a significant number of Americans traveling via direct flights from European hubs.
Chikungunya virus is transmitted through the bites of infected Aedes aegypti and Aedes albopictus mosquitoes — both of which are well established in Mauritius's tropical climate. The island has experienced multiple chikungunya outbreaks previously, including a severe episode that coincided with the broader 2005–2006 Indian Ocean epidemic, establishing a documented vulnerability to chikungunya reintroduction whenever sufficient vector density and susceptible populations are present.
The Indian Ocean Epidemic Context
The 2005–2006 Indian Ocean chikungunya epidemic was a turning point in the global recognition of this disease. Réunion Island — a French overseas territory immediately to the southwest of Mauritius — experienced an epidemic in which an estimated 266,000 people, approximately one-third of the total population, were infected in a single epidemic season. The outbreak was severe enough to generate excess mortality, primarily in older adults with underlying health conditions, and to overwhelm Réunion's healthcare system. It prompted emergency evacuation of some severe cases to mainland France and generated the first detailed epidemiological and clinical documentation of chikungunya at European-equivalent healthcare standards.
The 2025–2026 reemergence of chikungunya across the Indian Ocean — Mayotte (March 2026) and Mauritius (May 2026) are both within the same regional mosquito ecology as Réunion and the Comoros — reflects the cyclic nature of chikungunya outbreaks, which tend to occur when a sufficient proportion of the population has lost protective immunity from prior exposure, allowing the virus to find enough susceptible hosts for sustained transmission. These cycles have historically recurred every 7 to 15 years in endemic Indian Ocean regions.
Four Active Outbreaks and One Underused Vaccine
The current situation — four simultaneous active CDC chikungunya travel notices — makes a compelling case for American travelers to India, the Indian Ocean islands, the Caribbean, and South America to be specifically aware of chikungunya and to discuss the Ixchiq vaccine with their travel medicine provider before departure.
Ixchiq (VRC-CHKVLP059-00-VP), approved by the FDA in November 2023 and developed by Valneva, is a live-attenuated single-dose vaccine that requires no booster. It is approved for adults 18 and older at increased risk of chikungunya infection. Clinical trial data showed strong immunogenicity — more than 98 percent of vaccinated individuals achieved neutralizing antibody responses — with a safety profile similar to other live-attenuated vaccines. The most common side effects are mild reactogenicity: headache, fatigue, myalgia, and arthralgia that typically resolve within a week. These temporary post-vaccination symptoms are clinically similar to a mild version of the disease itself, which is the nature of live-attenuated vaccines, and should not be confused with actual chikungunya infection.
Despite its strong efficacy and single-dose convenience, Ixchiq remains dramatically underutilized among American travelers to chikungunya-risk regions. A large survey of travel medicine providers in 2025 found that fewer than 15 percent of patients traveling to endemic regions were offered or received chikungunya vaccination. With four simultaneous active outbreaks on the CDC's books as of mid-June 2026, that vaccination gap has direct consequences for returning travelers who will arrive home with a disease that causes weeks of intense joint pain and has no specific treatment.
Frequently Asked Questions
Q: What is the current chikungunya situation, and which countries are affected?
A: As of June 2026, the CDC has four simultaneous active chikungunya travel notices: Mauritius (May 14, 2026), French Guiana (June 4, 2026), Suriname (February 2026), and Mayotte (March 10, 2026).
Q: Why is Mauritius particularly vulnerable to chikungunya?
A: Mauritius has established Aedes aegypti and Aedes albopictus mosquito populations and has experienced prior major chikungunya epidemics, including during the devastating 2005–2006 Indian Ocean outbreak. Population immunity wanes over decades, creating cyclical vulnerability.
Q: Is there a vaccine against chikungunya?
A: Yes. Ixchiq is a single-dose FDA-approved live-attenuated vaccine for adults 18 and older at risk of chikungunya exposure. It requires approximately 28 days to generate full protection.
Q: What should travelers to Mauritius do to protect themselves?
A: Consult a travel medicine provider about Ixchiq vaccination at least 4 weeks before travel. Use EPA-registered DEET-based repellent, wear light-colored protective clothing, stay in air-conditioned accommodations when possible, and use mosquito nets where recommended.
Q: What does chikungunya feel like and how long does it last?
A: Sudden onset of fever above 103°F and severe joint pain affecting hands, wrists, ankles, and feet, typically for 7–10 days acutely. Up to half of patients develop chronic arthritis lasting months to years after recovery.
